# Article information:

ASCO: Novocure’s electric fields extend lung cancer survival  
<https://www.fiercebiotech.com/medtech/asco-novocures-tumor-treating-electric-fields-nearly-double-survival-some-lung-cancer>

# Article summary:

1. Novocure's Tumor Treating Fields technology has been shown to significantly improve the survival rate for patients with platinum-resistant, metastatic non-small cell lung cancer (NSCLC) in a phase 3 clinical trial.

2. The study found that adding TTFields to standard-of-care treatments increased median overall survival from 10 months to just over 13 months, and up to 18.5 months when combined with immune checkpoint inhibitors.

3. Novocure plans to submit the study results to the FDA for approval of TTFields' use in NSCLC and is also exploring introducing the therapy earlier in the treatment process for metastatic NSCLC.

# Article rating:

Appears moderately imbalanced: The article provides some useful information, but is missing several important points or pieces of evidence that would be required to present the discussed topics in a balanced and reliable way. You are encouraged to seek a more balanced perspective on the presented issues by exploring the provided research topics and looking at different information sources.

# Article analysis:

The article reports on Novocure's presentation of study results at the American Society of Clinical Oncology (ASCO) annual meeting, which showed that its Tumor Treating Fields technology (TTFields) can significantly improve the survival rate for patients with platinum-resistant, metastatic non-small cell lung cancer (NSCLC). The study involved 276 people with advanced NSCLC who had failed platinum-based therapies and were randomized to receive either standard-of-care treatment or a combination of one of the drugs and TTFields. The researchers found that those who had TTFields added to their treatment had a median overall survival rate of just over 13 months, compared to 10 months for those treated only with standard therapies.

The article provides some insights into potential biases and sources of partiality in its reporting. For example, it notes that Novocure is planning to submit the LUNAR study results to the FDA as part of a premarket approval application for TTFields' use in NSCLC, which suggests that there may be some promotional content in the article. Additionally, while the article does mention some limitations of the study, such as limited changes in median progression-free survival and adverse events experienced by almost all TTFields recipients during treatment, it does not explore any potential counterarguments or alternative perspectives on these findings.

Overall, while the article provides some useful information about Novocure's study results and their potential implications for treating NSCLC, readers should approach its claims with caution and seek out additional sources of information before drawing any firm conclusions.

# Topics for further research:

* Alternative perspectives on Tumor Treating Fields technology for NSCLC treatment
* Potential side effects of TTFields treatment for advanced NSCLC
* Comparison of TTFields with other emerging treatments for platinum-resistant NSCLC
* Long-term survival rates for NSCLC patients treated with TTFields
* FDA approval process for TTFields use in NSCLC treatment
* Novocure's financial interests in promoting TTFields for NSCLC treatment

# Report location:

<https://www.fullpicture.app/item/b7cf650cc4201af08cade6fe06fc3e55>